NUMAB
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics.
NUMAB
Industry:
Biopharma Biotechnology Health Care Health Diagnostics Life Science Medical Therapeutics
Founded:
2011-01-01
Address:
Wadenswil, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.numab.com
Total Employee:
11+
Status:
Active
Contact:
41445330471
Total Funding:
122 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ARNA Genomics
ARNA Genomics is a biotechnology company that specializes in developing fluid biopsy technology.
Beta Bugs Limited
Beta Bugs is an insect genetics company that develops and distributes high-performance Black Soldier Fly breeds to insect farmers.
Biomnigene
Biomnigene is a biotechnology agency that offers DNA/RNA extraction to microbiome analysis and research services.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Genomics
Genomics plc aiming to lead the genomic transformation of healthcare.
Imago BioSciences
Imago is a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs).
Libre Foods
Libre Foods is a biotech startup on a mission to liberate the food system and create a more free future for people, the planet and animals.
Oxitec
Oxitec develops an environment-friendly technology for the control of significant insect pests to prevent diseases and agricultural damage.
Current Advisors List
Advisor
Advisor
Board_member
2011-01-01
Board_member
2021-05-19
Board_member
2021-05-19
Board_member
2020-10-01
Board_member
2021-05-19
Current Employees Featured
David Urech CSO, and Co-CEO, Founder @ Numab
CSO, and Co-CEO, Founder
Oliver Middendorp CBO, Co-CEO, and Co-Founder @ Numab
CBO, Co-CEO, and Co-Founder
Peter Lichtlen CMO and Co-Founder @ Numab
CMO and Co-Founder
Tea Gunde Head of Pharmacology @ Numab
Head of Pharmacology
Sebastian Meyer Chief Operating Officer @ Numab
Chief Operating Officer
2017-08-01
Roland Helfenstein Chief Financial Officer @ Numab
Chief Financial Officer
2017-01-01
Founder
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Numab
HBM Partners
HBM Partners investment in Series C - Numab
BlackRock
BlackRock investment in Series C - Numab
Forbion Capital Partners
Forbion Capital Partners investment in Series C - Numab
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Numab
RTW Investments LLC
RTW Investments LLC investment in Series C - Numab
BVF Partners
BVF Partners investment in Series C - Numab
Novo Holdings
Novo Holdings investment in Series C - Numab
Octagon Capital Advisors
Octagon Capital Advisors investment in Series C - Numab
3sbio
3sbio investment in Series B - Numab
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-12 | 3sbio | Numab investment in Post-IPO Equity - 3sbio | 15 M CHF |
Official Site Inspections
http://www.numab.com Semrush global rank: 8.83 M Semrush visits lastest month: 245
- Host name: 212.243.197.113
- IP address: 212.243.197.113
- Location: Onex Switzerland
- Latitude: 46.1877
- Longitude: 6.0981
- Timezone: Europe/Zurich
- Postal: 1213
More informations about "Numab"
Numab Therapeutics AG
Numab Therapeutics AG Bachtobelstrasse 5 CH-8810 Horgen Switzerland Please contact us at info@numab.com. How to find us: By train & bus + Arriving at Zurich Airport, you reach us …See details»
Numab Therapeutics AG | About us
Prior to joining Numab in October 2021, James served as General Counsel for Waypoint Capital (US) and its healthcare fund Gurnet Point Capital from 2016 to 2021, and served on the board of Boston Pharmaceuticals, Tremeau …See details»
Numab - Crunchbase Company Profile & Funding
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It …See details»
Numab Therapeutics AG – Swiss Biotech
Numab offers its discovery and development capabilities to industry partners who are looking for innovative antibody-based products. ... Canton. Zurich; Facts & figures. Type of organization. …See details»
Numab - Org Chart, Teams, Culture & Jobs - The Org
Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, they are writing the next chapter in cancer immunotherapy by …See details»
Numab Company Profile 2024: Valuation, Funding
Numab General Information Description. Operator of a biopharmaceutical company intended to develop multispecific antibody-based immunotherapies. The company's platform reduces the random nature of the discovery process to …See details»
Numab Therapeutics AG - LinkedIn
Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap ...See details»
Numab Company Profile: Overview and Full News Analysis
Numab's lead program, NM26, is a bispecific antibody targeting IL-4Rα and IL-31 for the treatment of atopic dermatitis and other type 2 inflammatory disorders. They are also …See details»
Numab Therapeutics AG - Life-Sciences-Europe.com
Mar 28, 2017 Numab Therapeutics AG is a biopharmaceutical company discovering and developing next-generation therapies for cancer and auto-immune disease. We apply our …See details»
Numab - Leadership Team - The Org
The Leadership Team at Numab Therapeutics is responsible for setting the strategic direction and vision of the company, driving innovation in cancer immunotherapy. This team oversees …See details»
Numab - Funding, Financials, Valuation & Investors - Crunchbase
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases. Search Crunchbase. Start Free Trial . Chrome Extension. ... How many …See details»
Numab Company Profile - Office Locations, Competitors, Revenue …
Numab has 5 employees at their 1 location and $132.34 m in total funding,. See insights on Numab including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Numab - Contacts, Employees, Board Members, Advisors
Numab has 6 current employee profiles, including CSO, and Co-CEO, Founder David Urech. Numab has 7 board members and advisors, including Robert Kamen . ContactsSee details»
Numab Therapeutics AG - Venturelab
Jun 14, 2011 Numab Therapeutics AG: Our proprietary platforms Lambda-Cap™ and MATCH™ are designed to create differentiated therapeutics on a repeatable basis. Using a novel, …See details»
Numab Therapeutics - HBM Partners
Numab applies its proprietary antibody discovery and engineering technology to generate highly potent and stable antibody Fv fragments, which serve as building blocks to create mono- or …See details»
Numab Therapeutics Announces Series C Extension to CHF 180 …
Jan 9, 2025 CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors. Proceeds will be used to support the advancement …See details»
Baker McKenzie advises Numab Therapeutics in CHF 50 Million …
4 days ago Baker McKenzie advised Numab Therapeutics AG ("Numab Therapeutics"), a clinical-stage biotechnology company advancing a proprietary pipeline of multi-specific …See details»
ONO Enters into a Development and License Agreement with …
Mar 31, 2022 Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO, Gyo Sagara; “Ono”) today announced that it has exercised its option to enter into a development and …See details»
News - Numab Therapeutics AG
Feb 14, 2024 Numab Therapeutics AG today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new …See details»
ONO Enters into an Option and Collaboration Agreement with …
Feb 14, 2024 Numab will retain an opt-in right to develop and commercialize NM49 jointly with Ono in the United States. Ono will make an upfront payment to Numab upon execution of this …See details»